SEQUOIA-HCM Nearing Completion of Enrollment; On Track for Results in Q4 2023 Additional Data from Cohort 4 of REDWOOD-HCM to be Presented in Late-Breaking Clinical Trial Session at European Society of Cardiology Heart Failure 2023 Congress Company to Reduce Spending by More Than 10% in 2023 to Maintain Over 2 Years of Cash […]
Financial
iRhythm Technologies Announces First Quarter 2023 Financial Results
SAN FRANCISCO, May 04, 2023 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today reported financial results for the three months ended March 31, 2023. First Quarter 2023 Financial Results Revenue of $111.4 million, a 20.6% […]
Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress
Continued to advance leading pipeline of AAV cardiology and LV hematology assets; all 2023 milestones remain on track Updates on all four clinical programs and PKP2-ACM preclinical program to be presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Mark White, MB.ChB, named Chief Medical […]
BD Reports Second Quarter Fiscal 2023 Financial Results
BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges Revenue of $4.8 billion increased 1.5% as reported and 4.1% on a currency-neutral basis Revenue from base business (which excludes COVID-only diagnostic testing) grew 6.0% as reported, 8.7% currency-neutral GAAP and adjusted diluted […]
Teleflex Reports First Quarter Financial Results and Full Year 2023 Outlook
WAYNE, Pa., May 04, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended April 2, 2023. First quarter financial summary Revenues of $710.9 million, inclusive of five extra shipping days year-over-year, up 10.8% compared to the prior year period; up 13.2% on a […]
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in 2022, representing a 173% increase Q1 2023 CAPLYTA total prescriptions increased 159%, versus the same period […]
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
– Gibson Dunn Files Amended Complaint with Powerful New Evidence – ANN ARBOR, Mich., May 04, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) announced today that it has retained Gibson Dunn to vindicate its contractual rights against Daiichi Sankyo Europe (“DSE”) and filed an amended complaint against DSE in the […]
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million “As we look towards the remainder of the year, we will continue to focus on achieving our near-term milestones, including driving IBSRELA adoption, preparing to launch XPHOZAH in the second half of this year pending FDA approval, […]
Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., May 04, 2023 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the first quarter ended March 31, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update. Roger Jeffs, […]
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
– Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) has now completed last patient last visit and remains on track for topline month 30 registrational data to be announced in late July 2023 – Positive results announced in Cohort 5 of Phase 2 PROPEL 2 trial […]
